Opinion|Videos|December 3, 2024
Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
Author(s)Omar Nadeem, MD
Dr Nadeem discusses his approach to sequencing bispecifics vs chimeric antigen receptor T-cell therapies, including B-cell maturation antigen (BCMA) and non-BCMA bispecifics, and the factors he considers, followed by key takeaways from a recent meeting on bispecifics in relapsed/refractory multiple myeloma, focusing on dosing, adverse event management, and clinical pearls for oncologists.
Advertisement
Episodes in this series
Video content above is prompted by the following
- How do you approach sequencing (bispecifics vs chimeric antigen receptor T-cell or B-cell maturation antigen [BCMA] bispecific vs non-BCMA bispecific) in your practice?
- What factors do you consider?
- Please share your key takeaways from that meeting, especially surrounding the use of bispecifics (dosing, adverse event management) in relapsed/refractor multiple myeloma (R/R MM).
- What clinical pearls can you share with fellow medical oncologists considering the use of bispecifics in R/R MM?
Advertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5